NCT04555850View on ClinicalTrials.gov

A Phase 1b Study of Thymosin Beta 4 in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

July 30, 2018

Primary Completion Date

February 18, 2019

Study Completion Date

July 26, 2019

Conditions
Healthy
Interventions
DRUG

Recombinant Human Thymosin β4

Healthy subjects , were given a dose of rh-Tβ4 for ten consecutive days.

OTHER

Placebo

3 cohorts, with 6 healthy subjects , were given a dose of Placebo for ten consecutive days. Cohorts received ascending doses of either 0.5,2.0 or 5.0 ug/kg .

Trial Locations (1)

Unknown

Beijing Shijitan Hospital, Beijing

All Listed Sponsors
lead

Beijing Northland Biotech. Co., Ltd.

INDUSTRY

NCT04555850 - A Phase 1b Study of Thymosin Beta 4 in Healthy Volunteers | Biotech Hunter | Biotech Hunter